Abstract
It is generally accepted that active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, lentiviral vectors have emerged as promising tools for anti-tumor immunotherapy due to their capacity to transduce a wide range of different dividing and non-dividing cell types, including tumor cells and dendritic cells (DC). The latter are considered to be the key regulators of immunity and are therefore applied as ‘nature’s adjuvant’ in terms of eliciting strong antigen-specific cytotoxic T lymphocyte responses against tumor antigens. Therefore, lentiviral vectors have been carefully examined as gene transfer vehicles, be it for ex vivo or in vivo modification of DC and have been demonstrated to induce potent T cell mediated immune responses that can control tumor growth. Here, we review the use of lentivirally transduced DC and lentiviral vectors - as such - as an anti-tumor immunotherapeutic. Furthermore, we focus on the DC modulatory capacity of lentiviral vectors and the various efforts that have been made to improve the overall performance and safety of in vivo administration of lentiviral vectors. In conclusion, this review highlights the potential of lentiviral vectors as a generally applicable ‘off-the-shelf’ therapeutic for anti-tumor immunotherapy.
Keywords: Lentivirus, antigen-presenting cell, dendritic cell, cytotoxic T cell, cancer, immunotherapy
Current Gene Therapy
Title: Lentiviral Vectors for Anti-Tumor Immunotherapy
Volume: 8 Issue: 6
Author(s): Karine Breckpot, Perpetua U. Emeagi and Kris Thielemans
Affiliation:
Keywords: Lentivirus, antigen-presenting cell, dendritic cell, cytotoxic T cell, cancer, immunotherapy
Abstract: It is generally accepted that active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, lentiviral vectors have emerged as promising tools for anti-tumor immunotherapy due to their capacity to transduce a wide range of different dividing and non-dividing cell types, including tumor cells and dendritic cells (DC). The latter are considered to be the key regulators of immunity and are therefore applied as ‘nature’s adjuvant’ in terms of eliciting strong antigen-specific cytotoxic T lymphocyte responses against tumor antigens. Therefore, lentiviral vectors have been carefully examined as gene transfer vehicles, be it for ex vivo or in vivo modification of DC and have been demonstrated to induce potent T cell mediated immune responses that can control tumor growth. Here, we review the use of lentivirally transduced DC and lentiviral vectors - as such - as an anti-tumor immunotherapeutic. Furthermore, we focus on the DC modulatory capacity of lentiviral vectors and the various efforts that have been made to improve the overall performance and safety of in vivo administration of lentiviral vectors. In conclusion, this review highlights the potential of lentiviral vectors as a generally applicable ‘off-the-shelf’ therapeutic for anti-tumor immunotherapy.
Export Options
About this article
Cite this article as:
Breckpot Karine, Emeagi U. Perpetua and Thielemans Kris, Lentiviral Vectors for Anti-Tumor Immunotherapy, Current Gene Therapy 2008; 8 (6) . https://dx.doi.org/10.2174/156652308786848058
DOI https://dx.doi.org/10.2174/156652308786848058 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Zebrafish Stem Cell Differentiation Stage Factors Suppress Bcl-xL Release and Enhance 5-Fu-Mediated Apoptosis in Colon Cancer Cells
Current Pharmaceutical Biotechnology Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer
Drug Design Reviews - Online (Discontinued) It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands
Current Topics in Medicinal Chemistry Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Current Protein & Peptide Science Peptides in Melanoma Therapy
Current Pharmaceutical Design The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Strategies for Retargeted Gene Delivery Using Vectors Derived from Lentiviruses
Current Gene Therapy Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia Recent Trends in Nanotechnology-Based Drugs and Formulations for Targeted Therapeutic Delivery
Recent Patents on Inflammation & Allergy Drug Discovery Intrathyroidal Ectopic Thymus and Sonoelastographic Findings
Current Medical Imaging Recent Advances and Patents on Nanoscale Systems and Triggerable Drug Delivery in Medical Devices
Recent Patents on Biomedical Engineering (Discontinued) Clinical Evaluation of Natural History of Peyronie’s Disease: Our Experience, Old Myths and New Certainties
Inflammation & Allergy - Drug Targets (Discontinued) Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Metallothioneins and Platinum(II) Anti-Tumor Compounds
Current Medicinal Chemistry Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors
Recent Patents on Anti-Cancer Drug Discovery